CONTEXT:  More evidence of the increasing focus on RWE, with Aetion securing another significant round of funding.  The company reports doubling of revenues last year and is planning to expand in Europe and Asia-Pac.

IMPACT:  Medium

READ TIME:  2 mins


Quality Level Mean [1 – 10]:  7

1. “Ae­tion ini­tial­ly made its name by es­tab­lish­ing a part­ner­ship with the FDA and more re­cent­ly be­came the first RWE com­pa­ny to es­tab­lish an Covid-19 re­search col­lab­o­ra­tion with the agency.” 

2. “As reg­u­la­tors con­tin­ue to re­ly more on re­al world ev­i­dence, New York-based RWE leader Ae­tion said Tues­day that it has closed a $110 mil­lion Se­ries C fund­ing round, led by War­burg Pin­cus.” 

3. “The com­pa­ny said it will use the new funds to ex­tend the ca­pa­bil­i­ties of its RWE plat­form, used by many top bio­phar­ma com­pa­nies, ex­pand its Eu­ro­pean and Asian-Pa­cif­ic foot­print, and grow its com­mer­cial team to serve new clients.” 

4. “With for­mer FDA com­mis­sion­er Scott Got­tlieb serv­ing on the com­pa­ny’s board, Ae­tion al­so re­cent­ly poached the FDA’s top pol­i­cy of­fi­cial, Low­ell Schiller.” 

5. “In 2019, 48% of FDA drug ap­provals in­clud­ed RWE in sub­mis­sions, and in 2020, it was 75%, ac­cord­ing to Ae­tion analy­ses.” 

Source URL: https://endpts.com/rwe-takes-center-stage-as-aetion-bags-110m-series-c/